报价延迟最少15分钟:2025/07/20 19:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.25 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.18/-0.33
|
|
企业价值
620.12M
|
| 资产负债 |
|
每股账面净值
3.32
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
64.38M
|
|
每股收益
1.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 19:32 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
